Takeda & Biological E. Limited Announce Partnership to Develop Low-Cost Combination Vaccines for Low- & Middle-Income Countri...
2017年6月26日 - 4:06PM
ビジネスワイヤ(英語)
Two recently-signed agreements will transfer
Takeda’s measles and acellular pertussis vaccine technologies to
India-based multi-national company Biological E. Limited (“BE”) to
develop low-cost combination vaccines including diphtheria, tetanus
and acellular pertussis (DTaP) and measles-rubella (MR)
vaccines
Takeda Pharmaceutical Company Limited [TSE: 4502], (“Takeda”)
and Biological E. Limited (“BE”) today announced that they have
entered into a collaboration whereby two licensing agreements to
expedite the development and delivery of affordable combination
vaccines have been executed. BE will commercialize the vaccine in
India, China and low- and middle-income countries where large,
unmet public health needs exist.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170626005430/en/
Takeda has sold both the measles and pertussis vaccines in the
Japanese market for more than 20 years. In heavily populated
countries like India, where 25.7 million births occurred in 2015,
substantial opportunities remain to deliver critical vaccines to
those who need them. In the absence of access to vaccines in many
parts of the world, this partnership illustrates Takeda’s desire to
forge the kind of collaborations needed to overcome this public
health challenge in low- and middle-income countries.
“Access to medicines is one of Takeda’s core values, and these
agreements align with Takeda’s strategic goals to make high-impact
contributions to global public health, either alone or through
partners,” said Rahul Singhvi, Chief Operating Officer, Takeda
Vaccine Business Unit. “These two agreements along with our current
vaccine pipeline underscore our global commitment to address
important infectious diseases across the globe.”
Under these agreements, Takeda will conduct a transfer from
Japan to BE its existing measles and acellular pertussis vaccine
bulk production technology, including the provision of technical
services such as support in infrastructure review, training for
production and quality control, technical assistance in process
development, preclinical study design and production of clinical
batch and the first commercial batches.
BE will scale up the bulk production technology transferred from
Takeda and will be solely responsible for conducting and funding
development activities for the combination vaccines. BE has rights
to use Takeda’s measles vaccine technology for a combination MR
vaccine and the right to use Takeda’s pertussis vaccine technology
for any pertussis-containing combination vaccine. BE will have
commercialization rights for the MR and pertussis vaccines in
India, China and selected public markets worldwide as defined in
the agreements.
According to Mahima Datla, Managing Director at Biological E.
Limited, “At the core of our mission is to develop and
commercialize affordable vaccines. We have successfully
demonstrated this through our DTwP franchise in developing
countries, and this collaboration allows us to serve additional
markets and diversify our geographic presence. In the context of
MR, we look forward to contributing to the measles elimination
goals and protection against rubella.”
Takeda’s Commitment to Vaccines
Vaccines prevent more than two million deaths each year and have
transformed global public health. For 70 years, Takeda has supplied
vaccines to protect the health of people in Japan. Today, Takeda’s
global vaccine business is applying innovation to tackle some of
the world’s most challenging infectious diseases, such as dengue,
Zika, norovirus, and polio. Our team brings an outstanding track
record and a wealth of knowledge in vaccine development,
manufacturing and global access to advance a pipeline of vaccines
to address some of the world’s most pressing public health
needs.
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TSE: 4502) is a global,
research and development-driven pharmaceutical company committed to
bringing better health and a brighter future to patients by
translating science into life-changing medicines. Takeda focuses
its research efforts on oncology, gastroenterology and central
nervous system therapeutic areas plus vaccines. Takeda conducts
R&D both internally and with partners to stay at the leading
edge of innovation. New innovative products, especially in oncology
and gastroenterology, as well as its presence in emerging markets,
fuel the growth of Takeda. More than 30,000 Takeda employees are
committed to improving quality of life for patients, working with
our partners in health care in more than 70 countries. For more
information, visit http://www.takeda.com/news.
About Biological E. Limited
Biological E is a privately held company established in 1953.
Biological E. Limited (BE) is a globally focused biopharmaceutical
company that develops, manufactures and markets innovative vaccines
and biologics that respond to health care needs worldwide. The
company’s product development efforts are driven by an
internationally experienced management team and the company has
several strategic partnerships with leading biotechnology and
pharmaceutical companies and research institutes around the
world.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626005430/en/
Takeda Contacts:For media outside of Japan:Elissa J.
JohnsenTEL: + 1 224-554-3185elissa.johnsen@takeda.comorFor Japanese
media:Tsuyoshi TadaTEL:
+81-3-3278-2417tsuyoshi.tada@takeda.comorBiological E. Limited
Contact:Divya BijlwanHead, Business DevelopmentTEL:
+91-8008022323divya.bijlwan@biologicale.com